10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers

The collaboration extends 10x's clinical research initiatives beyond solid tumors into blood cancers for the first time.

Rhea-AI Summary

10x Genomics (TXG) announced a research collaboration with Fred Hutchinson Cancer Center to investigate single cell and spatial applications in cancer. This is 10x's first clinical research initiative extending beyond solid tumors into blood cancers.

The bladder cancer project plans to use Flex Apex and Xenium, with expansion to Atera planned, to study samples from patients with advanced disease. It aims to connect drug target expression and features of the tissue surrounding tumors with treatment response and clinical outcomes, exploring biomarkers that could eventually inform therapy selection.

The second project plans to use Flex Apex to investigate whether analysis of individual cells can improve detection of residual leukemia cells after treatment for acute myeloid leukemia. The teams also plan a framework for future clinical reporting to explore how these biological features could support cancer treatment planning.

Argus 15 min delay 22 alerts

-7.59% vs previous close $74.54 last price 5.9x rel. volume Open Argus

Details

Market move: TXG -7.59% vs previous close. oncology research partnership

$73.66 – $83.07 Day Range

$9.71B Market Cap

On Oct 7, the day this news came out, the latest delayed price for TXG is 7.59% below the previous close. Our momentum scanner has recorded 22 alerts for this stock so far that day. The latest delayed price is $74.54. Relative volume is exceptionally heavy at 5.9x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Terms

antibody-drug conjugates, immune checkpoint inhibitors, acute myeloid leukemia, clia-certified

4 terms

antibody-drug conjugates medical

"treated with antibody-drug conjugates, immune checkpoint inhibitors and other therapies"

A class of targeted cancer medicines that combine a lab-made antibody (which finds and sticks to specific markers on tumor cells) with a powerful cell-killing drug linked together so the toxic payload is delivered directly to the tumor. Think of it like a guided missile that reduces collateral damage compared with traditional chemotherapy; for investors, success or failure of these drugs drives clinical, regulatory and commercial value and can sharply affect a biotech company’s prospects and stock price.

immune checkpoint inhibitors medical

"treated with antibody-drug conjugates, immune checkpoint inhibitors and other therapies"

Drugs that release the immune system’s natural “brakes,” allowing immune cells to recognize and attack cancer cells; imagine taking the safety off a guard dog so it can chase intruders. They matter to investors because they can become high-value treatments with large sales potential, but their commercial success depends on clinical trial results, regulatory approval, competition and side-effect management, which all affect a company’s valuation.

acute myeloid leukemia medical

"residual disease detection in acute myeloid leukemia (AML)"

A fast‑moving blood cancer that starts in the bone marrow and crowd out healthy blood cell production, leaving the body short of normal red cells, white cells and platelets. It matters to investors because the disease creates urgent medical need, drives demand for new diagnostics and treatments, and so clinical trial results, regulatory decisions and drug pricing can rapidly change the commercial prospects and valuation of companies working on therapies.

clia-certified regulatory

"10x's planned CLIA-certified laboratory"

CLIA-certified means a laboratory has passed U.S. federal standards for performing tests on human samples, showing its results are accurate, reliable and timely. For investors this matters because certification is often required to sell clinical test services, bill insurers, win hospital or physician partnerships and avoid regulatory penalties — much like a restaurant passing a health inspection or a car getting a safety sticker before it can be sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Multi-project collaboration with Fred Hutch Cancer Center spans biomarker discovery in bladder cancer and a single cell approach to residual disease detection in acute myeloid leukemia

PLEASANTON, Calif., Oct. 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a multi-project research collaboration with Fred Hutchinson Cancer Center (Fred Hutch), one of the nation's leading cancer research institutions, to advance the use of single cell and spatial technologies in both solid tumor and hematologic malignancies.

The collaboration marks 10x's first clinical research initiative to extend beyond solid tumors into blood cancers, and builds on 10x's work to generate evidence for the clinical potential of its single cell and spatial products in oncology diagnostics.

The first project intends to use 10x's Flex Apex and Xenium platforms, with plans to expand to the Atera platform, to investigate tumor samples from patients with advanced bladder cancer treated with antibody-drug conjugates, immune checkpoint inhibitors and other therapies. The goal is to correlate drug target expression and tumor microenvironment features with treatment response and clinical outcomes. From there, the 10x and Fred Hutch teams will explore biomarkers that could one day help inform therapy selection for oncologists and their patients.

The second project intends to use the Flex Apex platform to investigate residual disease detection in acute myeloid leukemia (AML). Monitoring for residual leukemic cells after treatment is a critical part of guiding care for patients with AML, but today, it relies on a patchwork of separate technologies. 10x and Fred Hutch plan to investigate whether single cell analysis can improve and expand upon the current gold-standard methods.

Lawrence Fong, MD, will lead the collaboration for Fred Hutch. "This project will help us better characterize the cellular and molecular responses to cancer treatments. We look forward to seeing how the results of this research could help guide treatment decisions for people with cancer," said Fong, who is the scientific director of Fred Hutch's Integrated Immunotherapy Research Center and cares for patients with prostate, bladder and kidney cancers. Fong is also the Bezos Family Distinguished Scholar in Immunotherapy at Fred Hutch.

"Across cancer care, we have more effective therapies than ever, and too little insight into which patient will actually benefit from which one," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "Single cell and spatial biology let us look directly at the biology that drives treatment response, whether it's in a tumor or in the blood, and we believe that's the missing foundation for precision oncology. We're excited to work with Fred Hutch on this research."

This collaboration builds on 10x's announced collaborations with leading hospitals and institutes, and, together with 10x's planned CLIA-certified laboratory, builds the scientific and operational foundation for potential future diagnostic applications in oncology and autoimmune disease. As part of this effort, 10x and Fred Hutch also plan to build a framework for future clinical reporting, defining how single cell and spatial features could support treatment planning in patients with cancer.

About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics' products, services and collaborations. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K, 10-Q and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. 10x Genomics' products are for research use only (RUO) and are not for use in diagnostic procedures. "10x Genomics", "Atera," "Chromium," "Visium" and "Xenium" are trademarks or registered trademarks of 10x. 10x trademarks are the sole property of 10x, and are subject to legal protection in the United States and/or certain other countries.

Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-announces-new-collaboration-to-advance-single-cell-and-spatial-applications-across-solid-tumors-and-blood-cancers-302900198.html

SOURCE 10x Genomics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will 10x Genomics and Fred Hutch study in their cancer research collaboration?

The collaboration will investigate advanced bladder cancer and acute myeloid leukemia. The bladder cancer project will explore biological markers associated with treatment response and clinical outcomes. The leukemia project will investigate whether single cell analysis can improve and expand upon current methods for detecting residual disease after treatment.

Who will lead the Fred Hutch collaboration with 10x Genomics?

Lawrence Fong, MD, will lead the collaboration for Fred Hutch. He is scientific director of Fred Hutch's Integrated Immunotherapy Research Center and cares for patients with prostate, bladder and kidney cancers.